A combination of both antibodies might be applied to reduce the doses of bevacizumab and/or chemotherapeutics to increase the well‐being of patients suffering from glioma during their treatment, which is supported by our chemotherapy regimen combining TMD with anti‐VEGF‐ and anti‐EGFL7 treatment in experimental glioma. The gene discussed is VEGFA; the disease is central nervous system cancer.